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Heterogeneous upregulation of multiple prosurvival pathways underlies resistance to
damage-induced apoptosis in acute lymphoblastic leukemia (ALL) cells despite normal
p53 responses. Here, we show that the dual combination of insulin-like growth factor 1
(IGF1)/IGF1 receptor (IGF1/R) and mitogen-activated protein kinase/extracellular sig-
nal-regulated kinase (ERK) kinase (MEK) inhibition using AG1024 + U0126 can sensi-
tize apoptosis-resistant ALL cells to ionizing radiation-induced DNA damage
irrespective of effect of single pathway inhibition in vitro. This AG1024 + U0126 combi-
nation also significantly potentiates the ability of the core chemotherapy compounds
vincristine, dexamethasone, and daunorubicin to kill ALL cells in vitro. Evidence of
the synergistic action of AG1024 + U0126 in samples with variable basal levels of phos-
phorylated IGF1/Rb and ERK1/2 suggested additional targets of this drug combination.
Consistent with this, gene expression profiling identified 32 “synergy genes” differen-
tially targeted by IGF1/R +MEK inhibition and, among these, Signal transducer and
activator of transcription 6 (STAT6) and platelet-derived growth factor-associated protein 1
(PDAP1) were the most differentially downregulated cluster. Pearson correlation
analyses revealed that STAT6 and PDAP1 display significant expression codependency
and a common expression pattern linked with other key “synergy” genes, supporting
their predicted role in an STAT6ERKnuclear factor kappa beta (NF-kB) network.
Knockdown studies revealed that loss of STAT6, but not PDAP1, impinges on the cell
cycle, causing reduced numbers of viable cells. In combination with daunorubicin, STAT6
loss has an additive effect on cell killing, whereas PDAP1 loss is synergistic, indicating an
important role of PDAP1 in the cellular response to this anthracycline. Inhibition of STAT6
or PDAP1 may therefore represent a potential novel therapeutic strategy for resistant ALL
by enhancing sensitivity to chemotherapy. © 2018 ISEH-Society for hematology and Stem
Cells. Published by Elsevier Inc. This is an open access article under the CC BY license.
(http://creativecommons.org/licenses/by/4.0/)
TaggedPAlthough cure rates for childhood acute lymphoblastic
leukemia (ALL) have increased dramatically over
recent years through the integration of risk stratifica-
tion into treatment protocols [13], failure of
remission-inducing therapy is associated with only a
30% 10-year survival rate [4] and relapsed ALL
remains the most common cause of cancer-related
death in children [57]. There is a need for new thera-
peutic approaches with minimal toxicities for higher-
risk leukemias.
TaggedP hiladelphia-positive (Ph+) ALL is currently the
only ALL subset for which treatment includes molecu-
larly targeted treatment and the combination of imati-
nib with chemotherapy has significantly improved
survival rates in this subgroup [8]. Recent advances in
the molecular characterization of childhood ALL has
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Supplementary material associated with this article can be found,
in the online version, at doi:10.1016/j.exphem.2018.04.002.
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identified several new, risk-associated genotypes impli-
cating specific prosurvival signaling pathways [813].
Although these pathways potentially encompass multi-
ple molecular targets, the evident heterogeneity could
complicate a personalized treatment approach for ALL
patients. For example, hyperactivation of the receptor
tyrosine kinase and RAS signaling pathways is a promi-
nent feature of hypodiploid ALL and these cells demon-
strate sensitivity to phosphoinositide 3-kinase (PI3K), but
not mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK) kinase (MEK) inhibition in
vitro [14]. In contrast, high-hyperdiploid ALL with acti-
vating RAS mutations is responsive to MEK inhibition in
vitro [15]. Preclinical studies on adverse-risk Ph-like ALL,
which frequently harbors Janus kinase (JAK) and cytokine
receptor-like factor 2 (CRLF2) mutations, indicate sensi-
tivity to JAK inhibition and mammalian target of rapamy-
cin (mTOR)/PI3K inhibitors [10,16,17], whereas platelet-
derived growth factor beta (PDGFB)- and ABL-rearranged
Ph-like disease instead appear to display responsiveness to
the tyrosine kinase inhibitors imatinib and dasatinib
[8,18,19]. Consistent with these findings, our previous
work also showed that childhood ALL displaying both
poor clinical outcome and impaired apoptotic responses to
DNA damage in vitro exhibit heterogeneous upregulation
of multiple prosurvival pathways, which notably involves
the PI3K, insulin-like growth factor 1 (IGF1) and MAPK
pathways [20,21]. Hyperactivation of these pathways,
despite apparently normal p53 activation, causes sustained
nuclear factor kappa beta (NF-kB) activity and impaired
apoptosis after DNA damage [20]. Treatment with single
prosurvival pathway inhibitors could only sensitize ALL
cells to DNA damage in vitro in a patient-specific manner
[20,21].
TaggedP herefore, although it is clear that a significant pro-
portion of ALL patients are likely to benefit from a
molecularly targeted treatment added onto an existing
chemotherapy regimen, the heterogeneous deregulation
of signaling pathways paired with possible activation
of compensatory pathways may hamper sensitization of
ALL by single-pathway inhibition. We hypothesized
that targeting dual pathways might be more effective
against a broader spectrum of samples and indicate a
more applicable therapeutic approach for patients with
ALL showing impaired clinical responses. Here, we
show that the specific combination of IGF1/IGF1
receptor (IGF1/R) and MEK inhibition can synergisti-
cally sensitize primary ALLs to a range of cytotoxic
agents. We show that the mechanism of this drug com-
bination involves downregulation of signal transducer
and activator of transcription 6 (STAT6) and PDGF-
associated protein 1 (PDAP1), which appear to func-
tion in a predicted STAT6ERKNF-kB regulatory
network that may be implicated in apoptosis resistance
in childhood ALL.
Methods
Patient ALL samples
TaggedP atient bone marrow (BM) samples were collected from Bir-
mingham Children’s Hospital with ethical approval and writ-
ten consent (CCLG 08/H0405/22 and 08/H1208/4). Leukemic
BM mononuclear cells were separated by density centrifuga-
tion and frozen in a viable state before use. For clinical data,
see Supplementary Table E1 (online only, available at www.
exphem.org).
Annexin V/propidium iodide (PI) apoptosis analysis
TaggedPCells were treated with 5 Gy ionizing radiation (IR) and
incubated with U0126 (Promega, WI, USA), AG1024, or
LY294002 (Calbiochem, Darmstadt, Germany) at 37˚C for
24 hours, as described previously [21]. Apoptosis was
assayed using an Annexin V Apoptosis Kit (BD Pharmingen,
San Diego, CA) and analyzed using a Coulter Epics XL-
MCL flow cytometer (Beckman Coulter, Fullerton, CA).
Cells were considered to be apoptotic if they stained positive
for both Annexin V and PI (Ann+/PI+). The proportion of
IR-induced apoptotic cells was determined by subtracting the
proportion of apoptotic cells detected in the absence of IR.
Drug preparation and cytotoxicity assays
TaggedPU0126, AG1024, LY294002, vincristine, and daunorubicin
were dissolved in dimethylsulfoxide (DMSO) and dexametha-
sone in 100% ethanol at stock concentrations of 10 mmol/L.
Cells were incubated with U0126, AG1024, vincristine, dau-
norubicin, or dexamethasone (Sigma-Aldrich, St. Louis, MO,
USA) at the indicated doses at 37˚C for 72 hours and subse-
quently reacted with Cell TitreGlo reagent according to the
manufacturer’s instructions (Promega). Luminescence was
quantified using a Victor Wallac plate reader.
Western blotting
TaggedPWeston blotting was performed as described previously [21].
Antibodies included IGF1Rb (#3027), phospho-IGF1Rb
(Tyr1131)/insulin receptor b (Tyr1146) (#3021), ERK1/2
(137F5), phospho-ERK1/2 (Thr202/Tyr204) (D13.14.4E),
PDAP1 (#4300), procaspase 7 (D2Q3L), cleaved caspase 3
(5A1E) (Cell Signaling Technology, Danvers, MA, USA),
STAT6 (ab44718) (Abcam, Cambridge, MA, USA), and
PARP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Mouse monoclonal antibody against b-actin (AC-74) (Sigma-
Aldrich) served as a loading control.
Microarray analysis
TaggedPCells were untreated, treated with 5 Gy IR, 30 mmol/L
AG1024 + 5 Gy IR, 20 mmol/L U0126 + 5 Gy IR, or 30
mmol/L AG1024 + 20 mmol/L U0126 + 5 Gy IR for 6 hours
in vitro before RNA extraction using a combined TRIzol/
chloroform(Invitrogen)/RNeasy column purification (Qiagen)
method as described previously [21]. After first- and second-
strand synthesis and in vitro transcription, samples were
hybridized to HuGene1.0 ST v1 gene chips (Affymetrix,
Santa Clara, CA, USA). Probe-level quantile normalization
[22] and robust multiarray analysis [23] on the raw .CEL
files was performed using AltAnalyze [24]. Differentially
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expressed genes were identified using limma with a fold
change >1.5 and p < 0.01 [25].
siRNA silencing of STAT6 and PDAP1
TaggedPSmall interfering RNA (siRNA) silencing was performed in
HeLa cells using SiGenome SMARTpools targeting human
STAT6 (6778) and human PDAP1 (11333) (Thermo Scien-
tific, Waltham, MA, USA). Two daily sequential siRNA
treatments were performed using DharmaFECT transfection
(Thermo Scientific) according to the manufacturer’s instruc-
tions and nontargeting pool #2 (scrambled siRNA) served as
a control. Data from three separate knockdown experiments
are shown.
Cell cycle analysis
TaggedP reated cells were fixed in 100% ice-cold ethanol before staining
with PI (Sigma-Aldrich) and cell cycle profiles assessed using a
Coulter Epics XL-MCL flow cytometer (Beckman Coulter).
Statistical and network analysis
TaggedPCombination indices (CIs) were determined using dose
response curves and Calcusyn software and potentiation
effects (PEs) using paired Student t tests of data normalized
to untreated cells and with a single-agent effect subtracted.
Standard deviations are shown. Pearson correlation coeffi-
cients were determined by comparing normalized LOG2
expression values as described previously [26]. Network
analysis was performed by seeding synergy genes using Inge-
nuity Systems IPA software (Qiagen) according to the man-
ufacturer’s instructions.
Results
Combined IGF1/R and MEK inhibition using
AG1024 + U0126 sensitizes primary ALL cells to DNA
damage-induced apoptosis
TaggedPAs a consequence of the heterogeneous upregulation of
multiple prosurvival signaling pathways underlying
defective apoptotic responses in childhood ALL, we
reported previously that individual prosurvival pathway
inhibitors targeting MEK, IGF1/R, and PI3K induced
patient-specific responses to IR-induced DNA damage
in vitro [20,21]. We hypothesized that dual combina-
tion of prosurvival pathway inhibitors might sensitize a
broader range of leukemias and therefore inform of a
more applicable therapeutic approach. In this study, we
compared dual combinations of the IGF1/R, MEK, and
PI3K inhibitors AG1024, U0126, and LY294002,
respectively, at the same micromolar doses we reported
as single agents in our previous study [21]. We identi-
fied that the specific combination of AG1024 (IGF1/R
inhibitor) and U0126 (MEK inhibitor) was consistently
active in sensitizing four DNA damage-resistant
ALL to IR, whereas dual combinations involving
the PI3K inhibitor LY294002 induced more variable
responses (Figures 1A and B). The combination of
AG1024 + U0126 consistently induced the highest level
of IR-induced apoptosis, as measured by Annexin and
PI staining 24 hours after treatment (Figures 1A and
B), and this occurred irrespective of the sensitivity of
the cells to each single agent [21]. The drug vehicle
DMSO alone had minimal effect on the survival of pri-
mary ALL cells at the same doses even after 72 hours
(Supplementary Figure E1, online only, available at
www.exphem.org). In two representative samples,
western blotting confirmed that AG1024 + U0126 + IR
induced caspase- and PARP1-dependent apoptosis to a
greater extent than the single most potent inhibitor for
each leukaemia. (Supplementary Figure E2, online
only, available at www.exphem.org). Using dose
response curves (Supplementary Figure E3, online
only, available at www.exphem.org) and Calcusyn soft-
ware, we were able to determine CI values for ALL-
141, ALL-102, and ALL-106, which revealed strong
synergism, synergism, and a near additive effect
between AG1024 and U0126, respectively (Figure 1A
and Supplementary Table E2, online only, available at
www.exphem.org). For ALL-111, the dose curves for
both U0126 and AG1024 alone were inhibitory. We
therefore determined the PE that indicated a strongly
synergistic effect of the combined AG1024 + U0126
treatment (Figure 1B and Supplementary Figure E3 and
Supplementary Table E2, online only, available at
www.exphem.org). Therefore, whereas in ALL-141,
ALL-102, and ALL-111, the combined effect of
AG1024 + U0126 was synergistic, in ALL-106, the
combination of AG1024 + U0126 was not superior to
U0126 alone: both single-agent treatments exhibited
efficacy, as did the AG1024 + LY294002 combination.
Nonetheless, the sensitivity of ALL-106 to AG1024
and U0126 as single agents or in combination shows
that a treatment strategy targeting IGF1/R + MEK path-
ways would sensitize apoptosis-resistant primary ALL
cells to IR-induced DNA damage. We observed no syn-
ergistic effect of the two agents when combined in nor-
mal peripheral blood mononuclear cells in the presence
of IR-induced DNA damage (Supplementary Figure
E4, online only, available at www.exphem.org).
IGF1/R + MEK inhibition using AG1024 + U0126
sensitizes childhood ALL to core chemotherapy agents
TaggedPWe next investigated whether this specific combination
of IGF1/R +MEK inhibition could sensitize ALL cells to
other clinically relevant cytotoxic agents. To do so, we
tested whether AG1024 + U0126 would sensitize ALL to
the core remission-inducing chemotherapy agents dexa-
methasone, vincristine, and daunorubicin in vitro. We
evaluated the effect of the lower doses 1 and 10 mmol/L
AG1024 + U0126 on chemotherapy-induced killing after
72 hours in eight primary ALL samples and observed che-
mosensitization for all three drugs (Figure 1C). In combi-
nation with 100 nmol/L dexamethasone, synergism was
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Figure 1. The combined inhibition of IGF1/R + MEK pathways by AG1024 + U0126 sensitizes ALL cells to cytotoxic agents. (A) Representative
scatter plots of Annexin/PI staining in ALL-141 are shown. The average total percentage of apoptotic cells (Ann+/PI+, quadrant 2) induced by
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observed with 1 and 10 mmol/L AG1024 + U0126 (PE,
paired t tests, p = 0.0084 and p = 0.0166, respectively).
AG1024 + U0126 also increased ALL sensitivity to
100 nmol/L vincristine, with 1 mmol/L displaying an addi-
tive effect and 10 mmol/L displaying synergism (PE,
paired t test, p = 0.019). Finally, AG1024 + U0126 exerted
an additive effect with 10 nmol/L daunorubicin and,
although synergism was observed with 100 nmol/L dauno-
rubicin (paired t test, p = 0.01), the killing induced by dau-
norubicin alone was already very high and the incremental
change was small (not shown). The combination of IGF1/
R +MEK inhibition at micromolar doses is therefore able
to sensitize ALL cells, including high-risk and relapse
samples, to submicromolar doses of chemotherapy agents
in vitro.
Variable basal levels of MEK and IGF1/R activity
indicate additional mechanisms underlying the
synergistic action of AG1024 + U0126
TaggedPWe next set about investigating the possible mode of
action for the synergistic effect of AG1024 + U0126 in
sensitizing childhood ALL cells. To address this, we
investigated whether an association existed between the
basal levels of the phosphorylated ERK1/2, an indicator of
activated MEK pathway, and phosphorylated IGF1/Rb, an
indicator of activated IGF1 and insulin pathways, in 10
primary ALLs that were sensitive to the synergistic effect
of 10 mmol/L AG1024 + U0126 after 72 hours in vitro
compared with each of the single inhibitors in the absence
of other cytotoxic agents (PE, paired t test, p = 0.0001)
(Figure 2A). We did not observe a synergistic effect using
1 mmol/L AG1024 + U0126 (Supplementary Figure E5,
online only, available at www.exphem.org). These samples
(where material was sufficient) revealed highly variable
basal levels of phosphorylated ERK1/2 and IGF1/Rb pro-
teins (Figure 2B), suggesting that the synergistic action of
combined AG1024 + U0126 treatment was not wholly
dependent on targeting the MEK and IGF1/R pathways.
Combined AG0124 + U0126 treatment induces a
differential “synergy” gene profile
TaggedPBased on the variable basal levels of activated of MEK
and IGF1/R pathways, it appears that the synergistic
action of AG1024 + U0126 in ALL cells may function
in part through additional or off-target activity. To
explore possible additional mechanisms of this drug
combination, we employed gene expression profiling in
four ALLs, ALL-102, ALL-141, ALL-150, and ALL-
200, which displayed synergistic responses to
AG1024 + U0126. Samples were treated either with IR
to induce DNA damage, with each of the single inhibi-
tors + IR, or AG1024 + U0126 + IR for 6 hours. To
demonstrate that the individual inhibitors were active,
we first evaluated the alteration of known target genes
by comparing AG1024 + IR with IR alone and
U0126 + IR with IR alone. This comparison revealed
differential expression of known target genes for each
of the individual inhibitors, which, as well as MAPK
and G-protein-coupled receptor genes, included
miR222, SP1, and DUSP6 [27,28] for the MEK inhibi-
tor U0126 and JUN, SPRY, APAF1, and BAK1 [29] for
the IGF1/R inhibitor AG1024, as well as TNS3, previ-
ously correlated with IGF1 levels [30]. We subse-
quently compared gene expression in cells treated with
AG1024 + U0126 + IR with cells treated with each
inhibitor alone + IR to identify a set of “synergism”
genes that were differentially expressed after 6 hours
of treatment with AG1024 + U0126 (for Venn analysis,
see Supplementary Figure E6, online only, available at
www.exphem.org). Of the 32 differentially expressed
genes, six were consistently differentially upregulated
and 26 downregulated by AG1024 + U0126 + IR treat-
ment (Figure 2C). Because this set of genes could con-
tribute to apoptosis resistance in some ALL, we set
about investigating candidate synergy genes further.
Synergy genes STAT6 and PDAP1 exhibit codependent
expression
TaggedPOf the set of synergy genes we identified, STAT6 and
PDAP1 were among the most significantly differen-
tially downregulated (Figure 3A) and were validated
by independent quantitative reverse transcription poly-
merase chain reaction (Supplementary Figure E7,
online only, available at www.exphem.org). These
genes were of particular interest because of their possi-
ble role in high-risk subtypes of childhood ALL.
each treatment is shown, as well as the average IR-induced percentage of apoptosis (shown in parentheses), which were determined by subtract-
ing the background apoptosis from the IR plots. (B) The combination of AG1024 + U0126 (shaded) consistently sensitizes ALL cells to IR-
induced apoptosis regardless of the effect of AG1024 and U0126 as single agents in four cases (ALL-111, ALL-102, ALL-106, and ALL-141)
after 24 hours of treatment, as determined by Annexin V/PI staining. (The maximum concentration of DMSO reached in this experiment was
0.6% v/v DMSO.) CIs could be determined from individual drug dose curves (Supplementary Figure E3, online only, available at www.exphem.
org) for ALL-102 (++, moderate synergism), ALL-106 (+, nearly additive), and ALL-141 (+++, synergism). For ALL-111, the PE of the combi-
nation of AG1024 + U0126 was determined using unpaired t test analysis as described (***, strong synergism) (Supplementary Table E2, online
only, available at www.exphem.org). (C) AG1024 and U0126 together sensitize ALL (S025117, S032957, S026767, ALL-202, ALL-201R, ALL-
211, ALL-203, and ALL-212) to 100 nmol/L dexamethasone (top) 100 nmol/L vincristine (middle), and 10 nmol/L daunorubicin (bottom) after
72 hours of treatment. (The maximum DMSO concentration reached was 0.2% v/v DMSO.) The PE of AG1024 + U0126 with each drug was
determined using paired t test analysis. **p  0.005 indicates moderate synergism and *p  0.05 indicates synergism.
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Figure 2. The synergistic effect of combined inhibition of IGF1/R + MEK pathways by AG1024 + U0126 induces a distinct “synergy” gene sig-
nature. (A) In the absence of cytotoxic agents, primary ALL samples (n = 10) display synergistic sensitivity (PE = ***) to treatment with both
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Phosphorylated STAT6 has been reported to be ele-
vated in Ph+ ALL [31] and PDAP1 appears to be
involved in PDGF signaling [32,33], a pathway
recently implicated in apoptosis-resistant ALL [21] and
Ph-like ALL [812,18]. To provide some insight into
how these synergy genes might interact to induce che-
mosensitization when downregulated, we used logarith-
mic expression data from 20 arrays used in this study
(untreated, IR only, AG1024 + IR, U0126 + IR, and
AG1024 + U0126 + IR for each of the four ALL sam-
ples) to enable Pearson coefficient correlation analyses.
This identified a marked (r > 0.6) and highly signifi-
cant expression codependency between STAT6 and
PDAP1 (Figure 3B). When we compared a possible
relationship between STAT6 and PDAP1 and the
remaining synergy genes, we observed a striking pat-
tern of linked expression that was common to both
STAT6 and PDAP1 (Figure 3C).
Identification of a predicted regulatory network
underlying the synergistic activity of AG1024 + U0126
in ALL cells
TaggedPWe next performed network analysis using Ingenuity
software to determine whether the synergy genes that
we identified were predicted or known to interact in
common pathways. This analysis identified a major
network associated with cell death and survival, cellu-
lar function and maintenance, and hematological sys-
tem development and function. STAT6 and PDAP1
were associated with this network, of which STAT6
was a major component in addition to ERK and NF-
kB. In this STAT6ERKNF-kB network, STAT6 and
PDAP1 appeared to be closely associated (via PDGF),
consistent with our codependent expression data
(Figure 3D). Other components of this network
(PRDM8 and MPZL) had also shown linked expression
with both STAT6 and PDAP1 using Pearson correlation
analysis (see above). This STAT6ERKNF-kB net-
work could be an important mechanism underpinning
apoptosis resistance in ALL cells and warrants further
characterization.
Knockdown of STAT6 and PDAP1 has an impact on
cell cycle and chemosensitization
TaggedPBecause our data suggested that STAT6 and PDAP1
might contribute to apoptosis resistance, we hypothe-
sized that loss of these proteins individually might
reduce cell viability and/or sensitize cells to
chemotherapy. To address the cellular impact of loss
of STAT6 and PDAP1, we performed siRNA-mediated
knockdown in HeLa cells. Because of the difficulties in
obtaining gene knockdown in primary human ALL
cells, we used HeLa cells as an alternative since they
enable reproducible and effective protein knockdown.
Although HeLa cells are of a different tissue origin
than ALL, the rationale for choosing this model system
to explore the cellular impact of loss of these proteins
on chemotherapy sensitization was because they also
represent a widely accepted model for studying DNA
damage response proteins [34,35]. Figure 4A shows
reduction of each of the proteins after 72 hours of
siRNA treatment. Interestingly, we observed that the
loss of PDAP1 appeared to lead to an increase in
STAT6 protein expression. This apparent connection at
the protein level supports the codependent expression
correlations that we observed at the mRNA level for
these molecules.
TaggedPWe first investigated the impact of loss of each of
the proteins on cell viability and the cell cycle. In
untreated cells, STAT6 knockdown by siRNA treat-
ment had the greatest impact on the number of viable
cells, whereas PDAP1 loss had no impact on the num-
ber of viable cells after 1 week of siRNA treatment
(Figure 4B). When we assessed alterations in the cell
cycle, we found that, consistent with the reduction in
the number of viable cells and with previous findings
[36], STAT6 caused a 20% increase in the proportion
of cells in the G1 phase of the cell cycle, indicating an
increased number of arrested cells and a reduction in
cycling. In contrast, PDAP1 loss had no impact on the
cell cycle, which is consistent with the absence of
effect of PDAP1 loss on viable cell number
(Figure 4C).
TaggedPWe next investigated the ability of loss of each of
these proteins to sensitize cells to core chemotherapy
agents used to induce remission in ALL patients. When
we combined protein knockdown with increasing doses
of the anthracycline daunorubicin in vitro, the impact
on the total number of viable cells caused by knock-
down of STAT6 had an additive effect (Figure 4D),
whereas, strikingly, PDAP1 knockdown was synergistic
after 72 hours (Figure 4D). In contrast, when STAT6
was silenced, the impact on cell cycle arrest
(Figure 4D) reduced the sensitivity of HeLa cells to
increasing doses of vincristine, the mechanism of
which is dependent on cell proliferation. PDAP1
AG0124 + U0126 after 72 hours. (The maximum DMSO concentration reached was 0.2% v/v DMSO.) (B) Western blot analysis revealing sam-
ples displaying synergism to AG1024 + U0126 and variable basal MEK and IGF1/R pathway activity, as indicated by phosphorylation of IGF1/
Rb + IRb and ERK1/2, suggesting that additional mechanisms underlie the synergistic effect. (C) Heat map showing differential expression of
32 genes (“synergy” signature) induced by 6 hours of treatment with AG1024 + U0126 compared with the respective individual inhibitors + IR,
IR alone, and untreated cells in ALL-102, ALL-141, ALL-150, and ALL-200. *p  0.05 indicates synergism; ***p  0.0005 indicates strong
synergism.
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Figure 3. Predicted interactions of “synergy” genes STAT6 and PDAP1. (A) Heat map showing that STAT6 and PDAP1 are highly differentially
downregulated by AG1204 + U0126. (B) Pearson correlation coefficient analyses from 20 microarrays indicating that STAT6 and PDAP1 expres-
sion are highly codependent. (C) STAT6 and PDAP1 display common patterns of expression c-dependency with specific “synergy” genes
highlighted in bold text. (Pearson coefficient r values: below 0.4 = weak; 0.40.6 = modest; above 0.6 = marked codependency). (D) Ingenuity
network analysis predicting interaction of PDAP1 and STAT6 in a STAT6ERKNF-kB regulatory network seeded with “synergy” genes that
might be involved in apoptosis resistance (green = downregulated; red = upregulated). *p  0.05; **p  0.005; ***p  0.0005.
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Figure 4. Cellular consequences of siRNA-mediated knockdown of synergy genes. (A) Western blot showing siRNA mediated knockdown of
STAT6 and PDAP1 in HeLa cells. (B) siRNA-mediated knockdown of STAT6 results in a significant loss in cell viability, whereas PDAP1
knockdown has no impact after 1 week. (C) siRNA-mediated knockdown of STAT6 causes a 20% increase in cells in the G1 phase of the cell
cycle, indicating decreased proliferation, whereas PDAP1 knockdown has no impact on the cell cycle in HeLa cells. (D) Effect on loss of cell
viability by STAT6 knockdown leads to an additive effect with daunorubicin after 72 hours of treatment, whereas PDAP1 knockdown is syner-
gistic with daunorubicin at more than one dose in HeLa cells. *p  0.05; **p  0.005.
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knockdown had no effect at all on vincristine-induced
cell killing after 72 hours of treatment
(Supplementary Figure E8, online only, available at
www.exphem.org). The HeLa cells displayed no evi-
dence of sensitivity to dexamethasone with or without
knockdown (data not shown). These data support the
notion that the inhibition of pathways involving
STAT6 and PDAP1 contributes to the potentiating
effect of combined AG1024 + U0126 treatment on
DNA-damaging agents such as IR and daunorubicin.
The inability of loss of the single genes selected for
further exploration in this study to sensitize HeLa cells
to vincristine or dexamethasone suggests that it is
likely that alternative genes or a combination of genes
are implicated in sensitization observed in both HeLa
and leukemia cells. This is supported by the microarray
data. However, with respect to daunorubicin, our data
from HeLa cells indicate that STAT6, and in particular
PDAP1, appear to function in the cellular response to
daunorubicin and warrant further investigation in leu-
kemia cells.
TaggedPIn summary, we have identified a specific combina-
tion of prosurvival signaling pathway inhibitors,
AG1024 + U0126, which was consistently able to sensi-
tize apoptosis-resistant primary ALL cells to DNA-
damaging agents. This dual combination targets a spe-
cific set of “synergy” genes that includes STAT6 and
PDAP1, which are predicted to function in an
STAT6ERKNF-kB regulatory network.
Discussion
TaggedPChildhood ALL is genetically heterogeneous and deregu-
lation of different prosurvival signaling pathways can
contribute to apoptosis resistance. In this study, we
sought to determine whether the inhibition of a specific
combination of prosurvival pathways could sensitize
ALL irrespective of response to single pathway inhibition
and if this might inform of a more applicable uniform
treatment approach for ALL patients. We have shown
that the combined inhibition of the IGF1/R and MEK
pathways using AG1024 + U0126 can sensitize ALL cells
in a synergistic manner with IR-induced DNA damage
and can also potentiate the effects of core chemotherapy
agents in vitro. Gene expression profiling revealed a set
of synergy genes that included STAT6 and PDAP1, which
are predicted to function in a STAT6ERKNF-kB reg-
ulatory network.
TaggedPJAK/STAT signaling is implicated in many cancers
[36]. STAT6 hyperactivation has been described in a
several lymphoid malignancies and, recently, STAT6-
activating mutations have been identified in a range of
lymphomas with a frequency of up to 40% [3639]. In
ALL, phosphorylated STAT6 levels are elevated in
Ph+ disease [31] and, given the similarities, it is inter-
esting to speculate that STAT6 activity might also be
upregulated in the high-risk Ph-like ALL subtype.
STAT6 signaling has been implicated specifically in
treatment resistance and progression in several malig-
nancies, including the response of chronic lymphocytic
leukemia cells to B-cell receptor-mediated treatment
and radioresistance in inflammatory breast cancer cells
[4043]. There is mounting evidence, therefore, that
STAT6 signaling plays a relevant role in the patho-
physiology and clinical responses of lymphoid and
other malignancies. These data support our conclusions
that STAT6 is likely to be important in the cellular
response to DNA damage and could contribute to apo-
ptosis resistance in ALL.
TaggedPAlthough the function is largely unknown, PDAP1
was originally identified as a PDGF-interacting protein
[32]. Indeed, PDAP1 was shown recently to be an
effector of PDGR signaling in glioma cells and was
associated with proliferation and disease progression,
highlighting PDAP1 as a potential therapeutic target
[33]. PDGF signaling is a pathway that we recently
implicated in apoptosis resistance in childhood ALL
[21] and, furthermore, PDGFRB translocations are a
recurrent feature of high-risk ALL [812,18]. Interest-
ingly, cells with NF1 inactivation and consequential
hyperactivation of the RASMAPKERK signaling
pathway also display overexpression of PDGFRs,
which contributes to RAS-induced proliferation [44,45]
and supports a role for PDAP1 in a putative
STAT6ERKNF-kB regulatory network. In our
study, we showed that loss of PDAP1 synergized sig-
nificantly with daunorubicin to induce killing in HeLa
cells. We suggest that the role of PDAP1 in the cellu-
lar response to DNA-damaging agents should be inves-
tigated further in leukemia cells because PDAP1 might
represent an interesting novel therapeutic target for
chemosensitization.
TaggedPIn summary, through dual IGF1/R and MEK inhibi-
tion, we have identified a group of genes that appear to
contribute to impaired apoptotic responses to DNA
damage and, when targeted, can sensitize ALL cells to
chemotherapy agents. In particular, we have demon-
strated that STAT6 and PDAP1, via a putative
STAT6ERKNF-kB network, may represent useful
molecular targets for treatment-resistant ALL, particu-
larly in the absence of clinically available IGF1/R
inhibitors. It has already been demonstrated that JAK
inhibitors such as ruxolitinib or leflunomide, which
abrogate JAK3/STAT6 tyrosine phosphorylation, could
represent useful treatment approaches for some ALL.
A novel therapeutic approach for ALL could also
potentially include STAT6 inhibition. STAT6 small-
molecule inhibitors are currently under development
for the treatment of asthma and could also be evaluated
in the context of ALL. Overall, it will be important to
delineate STAT6/PDAP1 signaling precisely in ALL
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and other malignancies to elucidate the role of these
molecules in treatment resistance.
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Supplementary materials
TaggedP
Supplementary Table E1. Clinical features of paediatric ALL samples.
ALL Subtype Age (y) Cytogenetics WCC (50x109/L) MRD risk d28
S025117 cALL 3.1 ETV6-RUNX1 108 HR
S026767 T 7.08 n/k 121.4 nk
S027836 B 2.7 No results 13.5 LR
S029946 B 11 IgH@ 10.1 HR
S029947 B 2 High hyperdiploid 9.3 HR
S032957 B 5.11 High hyperdiploid 10.2 HR
S038556 B 9.9 High hyperdiploid 33.8 LR
ALL-75 T 7 2xp16del 193 nk
ALL-102 cALL 7.02 Hyperdiploid (52) 62 HR
ALL-106 cALL 15 Near Haploid (28) 117 HR
ALL-111 cALL 10.09 Gain of AML1 2 HR
ALL-115 T 4.1 Mybdup nk LR
ALL-141 cALL 14 Gain of ETV6 11 HR
ALL-150 B 8 ETV6-RUNX1 nk LR
ALL-200 B 4.06 nk 142 nk
ALL-201R BCP-ALL 17.5 IGH@ na na
ALL-202 cALL 6.08 46,XX Subclone of IGH@ gain 3 LR
ALL-203 cALL 2.10 CRLF2 rearranged 17.6 HR
ALL-211 T 7.05 TCRD-LM02 405 LR
ALL-212 T 5.07 46, XY 140 LR
ALL-213 T 8 SIL-TAL1 493 HR
Nk, not known; na, not applicable, HR, High risk; LR, Low risk.
Supplementary Table E2. Combined effect of U0126+AG1024 in ALL treated with
IR.
ALL Combined effect of U0126+AG1024
ALL-141 CI=0.478 +++ synergism
ALL-102 CI=0.714 ++ moderate synergism
ALL-106 CI=1.020 + nearly additive
ALL-111 PE, p<0.0001 *** very strong synergism
PE, potentiation effect; CI, combination indices.
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Supplementary Figure E2. Western blot analysis comparing caspase-dependent apoptosis induced by AG1024+U0126 with the single most
potent single inhibitor 8h following treatment in two representative ALL (ALL-111 and ALL-141). In ALL-111, which exhibited equal sensitiv-
ity to LY294002 and U0126+AG1024, caspase and PARP cleavage were comparable following 8h treatment. In the completely IR-resistant leu-
kaemia, ALL-141, caspase and PARP1 cleavage was significantly induced by treatment with U0126+AG1024 compared with AG1024 alone, the
only single inhibitor with some effect.
Supplementary Figure E1. Graphs show minimal effect on survival of cells from 5 representative primary ALL samples following 24h and 72h
treatment with doses of DMSO (drug vehicle) reflecting those doses reached within the experimental data (<0.6% DMSO). In contrast, 1%
DMSO did cause a cytotoxic effect after 72h.
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Supplementary Figure E3. Graphs show dose-curves for U0126
and for AG1024 for four ALLs which were used for Calcusyn analy-
sis to determine the effect of combined U0126+AG1024 treatment.
Supplementary Figure E4. Graph shows absence of a combined
effect of AG1024+U1026 on IR-induced apoptosis in peripheral
blood mononuclear cells (PBMCs) from three healthy individuals,
measured by Annexin V/PI staining and FACS analysis after 72h.
Supplementary Figure E5. Graph shows no synergism between
AG1024 and U0126 at a dose of 1mM following 72h treatment in 10
primary ALL.
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Supplementary Figure E6. Identification of genes contributing to AG1024+U0126 synergism. Venn analysis identifying ‘synergy’ genes shows
26 genes are differentially down-regulated (left) and 6 genes are differentially upregulated (right) by treatment of ALL cells with AG1024
+U0126+IR compared with AG1024+IR and U0126+IR in samples ALL-102, ALL-141, ALL-150 and ALL-200.
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
ARTICLE IN PRESS
12.e4 V. Weston et al. / Experimental Hematology 2018;00:00-00
Supplementary Figure E7. Independent qRT-PCR validation of the most differentially altered ‘synergy’ genes, STAT6 and PDAP1, in ALL
employed in the microarray analysis as well as others treated under the same conditions.
Supplementary Figure E8. Sensitization of HeLa cells by siRNA silencing of ‘synergy’ candidate genes, STAT6 and PDAP1. Graphs show the
decrease in cell proliferation caused by STAT6 knockdown protects HeLa cells from vincristine-induce killing whereas PDAP1 knockdown has
no effect compared with scrambled siRNA, following 72h treatment in vitro.
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